ReviewNature reviews. Endocrinology2022
Modelling metabolic diseases and drug response using stem cells and organoids.
Review in Nature reviews. Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 85 citations in OpenAlex.
- Using Organoids to Unlock the Potential of Human Torpor for Spaceflight.Current stem cell reports · 2026Article
- The sixth sense of the brain: interoception in organoid study.Bone research · 2026Review
- Liver Organoids: From Disease Modelling to Regenerative Medicine.Cell proliferation · 2026Review
- Modeling physiological insulin sensitivity and pre-diabetic insulin resistance in multiple hPSC-derived cell types.Signal transduction and targeted therapy · 2026Article
- Integrating CRISPR genome editing with liver organoid and hiPSC-derived microfluidic platforms to model metabolic dysfunction-associated steatotic liver disease.Biochemistry and biophysics reports · 2026Review
- Electroacupuncture as a therapeutic intervention for obesity: mechanisms and implications.Pflugers Archiv : European journal of physiology · 2026Review
- Single-cell sequencing and organoids: applications in organ development and disease.Molecular biomedicine · 2025Review
- Adipogenic characterization of immortalized CD55Adipocyte · 2025Article
- Expansion of human hepatocytes and their application in three-dimensional culture and genetic manipulation.Nature protocols · 2025Article
- Development of vascularized adipose organoids from PBMSCs and their application in evaluating Celastrol's effects.Adipocyte · 2025Article
- Organ-on-a-Chip: A Roadmap for Translational Research in Human and Veterinary Medicine.International journal of molecular sciences · 2025Review
- Reaction-Guided Metabolomics Accelerates High-Throughput Annotation of Xenobiotic Metabolites for Human Exposome.Environmental science & technology · 2025Article
- Silent saboteurs: How microplastics disrupt stem cells and tissue regeneration.World journal of stem cells · 2025Review
- Human iPSC-derived salivary gland organoids model diabetic salivary gland dysfunction.bioRxiv : the preprint server for biology · 2025Article
- Microenvironmental determinants of cancer progression during obesity: emerging evidence and novel perspectives.Journal of translational medicine · 2025Review
- Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering.Cell reports. Medicine · 2025Review
- Gut Microbiota-Derived Metabolites Orchestrate Metabolic Reprogramming in Diabetic Cardiomyopathy: Mechanisms and Therapeutic Frontiers.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Towards a Better Understanding of the Human Health Risk of Per- and Polyfluoroalkyl Substances Using Organoid Models.Bioengineering (Basel, Switzerland) · 2025Article
- Extracellular Vesicles in Gut-Bone Axis: Novel Insights and Therapeutic Opportunities for Osteoporosis.Small science · 2025Review
- From gut to liver: organoids as platforms for next-generation toxicology assessment vehicles for xenobiotics.Stem cell research & therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in stem cell and organoid technology allow the generation of cellular models that replicate the histological, molecular and physiological properties of human organs. Combined with marked improvements in gene editing tools, human stem cells and organoids provide unprecedented systems for studying mechanisms of metabolic diseases. Here, we review progress made over the past decade in the generation and use of stem cell-derived metabolic cell types and organoids in metabolic disease research, especially obesity and liver diseases. In particular, we discuss the limitations of animal models and the advantages of stem cells and organoids, including their application to metabolic diseases. We also discuss mechanisms of drug action, understanding the efficacy and toxicity of existing therapies, screening for new treatments and pursuing personalized therapies. We highlight the potential of combining stem cell-derived organoids with gene editing and functional genomics to revolutionize the approach to finding treatments for metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.